類風濕關節炎:全球醫藥品市場(2011∼2021年)

本報告提供全球類風濕關節炎市場相關調查分析，彙整主要產品到2021年為止的收益預測，各地區趨勢，研究開發，市場競爭和機會等資料，為您概述為以下內容。

第1章 摘要整理

第2章 類風濕關節炎的簡介

• 何謂類風濕關節炎
• 關節的理解
• 類風濕關節炎的原因
• 類風濕關節炎的診斷
• 危險因素
• 類風濕關節炎的管理
• 類風濕關節炎的經濟成本
• 類風濕關節炎的全球得病率
• 類風濕關節炎發病的不確定性

第3章 類風濕關節炎的治療

• 類風濕關節炎治療所採用的藥物
• 止痛藥
• 皮質類固醇
• 抗類風濕關節炎劑
• 治療類風濕關節炎的生物製劑
• 類風濕關節炎市場上主要治療方法

第4章 全球類風濕關節炎市場:2011∼2021年

• 全球類風濕關節炎市場:2011∼2021年
• 類風濕關節炎的非生技藥品
• 類風濕關節炎的生技藥品市場預測
• 市場摘要

第5章 類風濕關節炎市場上主要藥物:2011∼2021年

• 非類固醇抗發炎藥(NSAID)
• 生技藥品

第6章 類風濕關節炎的研究開發平台:2011年

• NSAID
• 皮質類固醇
• 生技藥品

第7章 主要國家市場

• 主要國家市場
• 美國
• 日本
• 歐洲
• 新興經濟
  • 中國
  • 印度
• 其他地區
• 各國市場預測摘要

第8 主要企業

• 簡介
• Roche
• Abbott Laboratories
• Amgen
• Johnson & Johnson
• Biogen Idec

第9章 推動市場因素和阻礙因素

• SWOT分析
• 商業的推動要素
• 商業的阻礙要素
• 結論

第10章 專家的見解

第11章 結論

圖表

Abstract

Report Details

Now discover trends, opportunities and revenue prospects for treating rheumatoid arthritis

Where's the arthritic treatment market heading? Visiongain's updated report gives you forecasted revenues to 2023 for drugs treating human rheumatoid arthritis (RA). There you find R&D trends, outlooks and commercial opportunities.

Our study lets you assess sales data and predictions for the world RA medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.

Established and emerging anti-rheumatic technologies have potential. Read on to scan features of that industry, find what drives it, and see what its future market could be worth.

Forecasts and other analyses to help you understand the RA market

Our report gives you revenue forecasts to 2023, historical data, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and developments (R&D). You also gain 56 tables, 47 charts and three research interviews.

With our study you can stay ahead in knowledge, benefiting your research, analyses and decisions. There you find trends, innovations and opportunities for treating rheumatoid arthritis. You see what's happening, discovering possibilities.

There's rising need worldwide for drugs to treat arthritis. For RA medicines, our work helps you find business areas that can prosper most, reducing the risk of your missing out.

The following sections, then, show how you benefit from our new study.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market for treating RA, our work shows forecasts to 2023 for submarkets:

• Biologics (biological drugs, e.g. monoclonal antibodies [mAbs])
• Non-biologics (other therapeutic molecules).
• For the non-biologics submarket, you get further revenue breakdowns to 2023:
• NSAIDs
• Conventional DMARDs
• Others agents (grouped, including novel DMARDs and corticosteroids).
• From 2013, how will the RA drugs market grow? Which areas will most prosper? For anti-rheumatic medicines, our report helps you identify growth potential and find opportunities.

See prospects for manufacturers of novel drugs, generics and biosimilars, including follow-on and next-generation products.

Also our investigation discusses what stimulates and restrains business. There you explore dynamics of that industry, also seeing what products can achieve the most success.

See revenue forecasts for leading drugs

How will leading anti-arthritic agents perform to 2023 at world level? Our study forecasts sales of 10 leading RA products and one emerging drug:

• Celebrex
• Arcoxia
• Remicade
• Humira
• Enbrel
• Orencia
• Simponi
• Actemra
• Cimzia
• Xeljanz.

There you discover how high sales can go, to 2023, finding drugs and years with highest predicted revenues and growth. Also, you see how competitors compare - assess competition. You find what's happening, understanding trends, challenges and opportunities.

Our analysis also divides its overall world RA revenue forecast into those for main geographical markets.

What prospects for leading regions and countries?

In developed and developing countries - especially India and China - there remain many opportunities for selling drugs to treat rheumatoid arthritis. There you see opportunities for developers, producers and sellers of those medicines.

Our study shows you individual revenue forecasts to 2023 for eleven national markets:

• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

There you discover progress and outlooks. That way, you assess the industry's future - hear about developments and find their significance.

Our forecasting shows revenue growth will occur in established pharma markets and in developing countries. In particular, product launches from 2013 to 2023 will change anti-rheumatic drug prescribing and the commercial landscape. See how.

Research and development - assess innovation, trends and possibilities

What about R&D - the pipeline for new RA drugs? You see developmental trends for these agents and others:

• Biologics, including biosimilars
• Corticosteroids
• Other agents (e.g. JAK inhibitors).

In our work you assess innovations, hearing about developments and finding their significance. Discover progress.

See, then, what the future holds. For large companies and specialty pharma firms there exist many opportunities in treating rheumatoid arthritis. Our study explains, discussing many issues.

What affects the anti-arthritics drug sector?

Our report discusses issues and events affecting that industry and market from 2013, including these developments:

• Current and future use of treatments
• Unmet and under-met needs for treating rheumatoid arthritis
• Janus kinase inhibitors and anti-TNF therapy
• Adverse effect profiles and patient compliance
• Regulatory challenges and developments
• Novel small-molecule therapies
• Demand for more-efficacious and better-tolerated drugs
• Biosimilars - a threat to original novel products?

That way, you explore technological, economic, social and political (STEP) questions, assessing outlooks for that area of business.

Our investigation also lets you analyse the RA treatment industry's strengths, weaknesses, opportunities and threats (SWOT). See, then, what the future holds.

Leading companies and 2017 market value

What happens next? Our study predicts the overall world market for anti-arthritic drugs will reach $38.5bn in 2017. There, you also see how that market performs to 2023.

Our analyses show you what products and organisations there hold greatest potential. That work explores these leading five companies and others:

• Abbott Laboratories (AbbVie)
• Roche
• Pfizer
• Johnson & Johnson
• Amgen.

Also, you read three interviews with authorities on that field. See what shapes it, discovering what participants think, feel, do and say.

Prospects for R&D on arthritis are encouraging, and from 2013 onwards there will arise many opportunities. Our work shows you technological, medical and commercial possibilities, helping you stay ahead.

Ten ways Rheumatoid Arthritis (RA): World Drug Market 2013-2023 helps you

In particular then, our investigation gives you the following knowledge:

• Revenues to 2023 for the world RA drugs market - discover that industry's overall sales prospects
• Revenues to 2023 for 5 world-level submarkets - investigate the potential of that industry's components, finding the most-promising areas for investments and revenues
• Revenues to 2023 for 11 products - find sales outlooks for top brands, seeing how they can compete and succeed
• Forecasts to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - see national sales potentials, finding the best regions for revenues and growth
• Review of R&D for treating rheumatoid arthritis - investigate progress in its research areas, finding technological and medical possibilities
• Discussions of leading companies, including profiles of the top 5 players - hear about strategies, capabilities, results and outlooks
• Interviews with authorities in that field - discover debates and opinions to help you stay ahead
• Competition and opportunities - see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
• Analysis of what stimulates and restrains the industry and market - assess challenges and strengths, helping you compete and gain advantages
• Prospects for established competitors and firms seeking to enter the sector -explore needs, practices and outlooks for future success.

You gain information found nowhere else

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.

Table of Contents

Table of Contents

1. Executive Summary

• 1.1 Main Findings of the Study
• 1.2 Aims, Scope and Format of the Report
• 1.3 Chapter Outlines
• 1.4 Research and Analysis Methods

2. Introduction to Rheumatoid Arthritis

• 2.1 What is Rheumatoid Arthritis?
• 2.2 Understanding Joints
• 2.3 What Causes Rheumatoid Arthritis?
  • 2.3.1 Over Active Immune System: The Immune Response and Inflammation Process
  • 2.3.2 Genetic Factors
  • 2.3.3 Environmental Trigger: Infection
  • 2.3.4 Other Environmental Triggers
• 2.4 Signs and Symptoms of RA
• 2.5 Similar Disorders
• 2.6 Risk Factors for Rheumatoid Arthritis
• 2.7 Prevalence of Rheumatoid Arthritis
• 2.8 Economic Impact of the Disease
• 2.9 Uncertainty on the Incidence of Rheumatoid Arthritis

3. Treatment of Rheumatoid Arthritis

• 3.1 Drug Treatment of Rheumatoid Arthritis
• 3.2 Analgesics (Pain Relieving Drugs)
  • 3.2.1 Narcotics
  • 3.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 3.3 Corticosteroids (Glucocorticoids)
• 3.4 DMARDs
  • 3.4.1 Conventional DMARDs
  • 3.4.2 New Oral DMARDs
  • 3.4.3 Biologics (Biological Drugs)

4. The World Market for Rheumatoid Arthritis Drugs, 2013-2023

• 4.1 The Global Rheumatoid Arthritis Market in 2011
• 4.2 The Global Rheumatoid Arthritis Market: Revenue Forecast, 2012-2023
• 4.3 Non-Biologics for RA
  • 4.3.1 NSAIDs: Market, 2011-2023
  • 4.3.2 Conventional DMARDs: Market, 2011-2023
  • 4.3.3 The Others Submarket, Including Novel Oral DMARDs, is Growing in Prominence
• 4.4 Biologics for RA: Market Forecast, 2012-2023
• 4.5 Summary of the Market

5. Leading Drugs in the Rheumatoid Arthritis Market, 2013-2023

• 5.1 The Main Drugs in the RA Market, 2011
• 5.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 5.2.1 Celebrex: Revenue Forecast, 2012-2023
  • 5.2.2 Arcoxia: Revenue Forecast, 2012-2023
• 5.3 Biologics
  • 5.3.1 Remicade: Revenue Forecast, 2012-2023
  • 5.3.2 Humira: Revenue Forecast, 2012-2023
  • 5.3.3 Enbrel: Revenue Forecast, 2012-2023
  • 5.3.4 Rituxan: Revenue Forecast, 2012-2023
  • 5.3.5 Orencia: Revenue Forecast, 2012-2023
  • 5.3.6 Simponi: Revenue Forecast, 2012-2023
  • 5.3.7 Actemra: Revenue Forecast, 2012-2023
  • 5.3.8 Cimzia: Revenue Forecast, 2012-2023
• 5.4 Janus Kinase Inhibitors: Newly Approved Xeljanz
  • 5.4.1 Xeljanz: Revenue Forecast, 2012-2023
• 5.5 Summary of the Leading RA Drugs

6. Leading National Markets: Rheumatoid Arthritis Drugs, 2013-2023

• 6.1 The Leading National Markets in 2011
• 6.2 Leading National Markets: Revenue Forecasts, 2012-2023
  • 6.2.1 The US RA Market: Revenue Forecast, 2012-2023
  • 6.2.2 The Leading European RA Markets: Revenue Forecast, 2012-2023
  • 6.2.3 The Japanese RA Market: Revenue Forecast, 2012-2023
  • 6.2.4 The Chinese RA Market: Revenue Forecast, 2012-2023
  • 6.2.5 The Brazilian RA Market: Revenue Forecast, 2012-2023
  • 6.2.6 The Indian RA Market: Revenue Forecast, 2012-2023
  • 6.2.7 The Russian RA Market: Revenue Forecast, 2012-2023
• 6.3 Summary of the Leading National Markets

7. Rheumatoid Arthritis: R&D Pipeline, 2013

• 7.1 R&D Pipeline: Corticosteroids for Rheumatoid Arthritis, 2013
  • 7.1.1 Pfizer's PF-04171327
• 7.2 R&D Pipeline: New Biologics for Rheumatoid Arthritis, 2013
  • 7.2.1 Novartis' Secukinumab
  • 7.2.2 Johnson & Johnson's Sirukumab
• 7.2.3 Sanofi's Sarilumab
• 7.3 R&D Pipeline: Biosimilars for Rheumatoid Arthritis, 2013
  • 7.3.1 Celltrion's Remsima
  • 7.3.2 EMS' Reumatocept
  • 7.3.3 TSH Biopharm's ENIA11
  • 7.3.4 Boehringer Ingelheim's BI695500
  • 7.3.5 Hanwha Chemical and Merck's HD 203
• 7.4 R&D Pipeline: Other Treatments for Rheumatoid Arthritis, 2013
  • 7.4.1 Eli Lilly's Baricitinib
  • 7.4.2 AstraZeneca's Fostamatinib
  • 7.4.3 AB Science's Masitinib
  • 7.4.4 Ablynx's ALX-0061: a Nanobody for RA
• 7.5 iRHOM2: A Potential New Drug Target for RA

8. Leading Companies in the RA Drugs Market, 2013

• 8.1 Introduction to the Leading Companies
• 8.2 Abbott, Now AbbVie, Dominates the Market
• 8.3 Roche Markets Rituxan and Actemra
• 8.4 Pfizer: Xeljanz Will Maintain Strong Position in RA Drug Market
• 8.5 Johnson & Johnson: 24% of Revenue Generated by RA Drugs
• 8.6 Amgen: High Revenues from RA Drugs

9. Qualitative Analysis of the Rheumatoid Arthritis Drug Market, 2013-2023

• 9.1 Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2013
  • 9.1.1 Rheumatoid Arthritis: Management Rather Than Cure
  • 9.1.2 The Market Can Support a Wide Range of Products
  • 9.1.3 The Promising R&D Pipeline
  • 9.1.4 Adverse Effect Profiles and Poor Patient Compliance Rates
• 9.2 Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2013-2023
  • 9.2.1 The Introduction of Novel Small Molecule Therapies Will Drive Market Growth
  • 9.2.2 The Penetration of Therapies into the Emerging Markets
  • 9.2.3 The Demand for Drugs With Higher Rates of Therapeutic Success
  • 9.2.4 The Introduction of Biosimilars: A Threat to the Market?
• 9.3 Social, Technological, Economic and Political Factors Affecting the Rheumatoid Arthritis Market (STEP Analysis), 2013-2023
  • 9.3.1 Social Factors Influencing the RA Drug Market
  • 9.3.2 Technological Factors Influencing the RA Drug Market
  • 9.3.3 Economic Factors Influencing the RA Drug Market
  • 9.3.4 Political Factors Influencing the RA Drug Market

10. Research Interviews

• 10.1 Interview with Dr Tuulikki Sokka, MD, PhD, Head of Rheumatology, Jyväskylä Central Hospital, Finland
  • 10.1.1 On Current and Future Use of Treatments for RA
  • 10.1.2 On Unmet Needs in the RA Therapy Market
  • 10.1.3 On the R&D Pipeline for Rheumatoid Arthritis
  • 10.1.4 On Drivers of the RA Therapy Market
  • 10.1.5 On Prevalence of RA Around the World
• 10.2 Interview with Dr Yusuf Yazici, MD, Assistant Professor, Department of Medicine-Rheumatology and Hospital for Joint Diseases and Medicine, New York University
  • 10.2.1 Opinion on the Key Unmet Needs for RA Treatments
  • 10.2.2 Opinions on Current Treatments
  • 10.2.3 Views on Abatacept: New Biologic for RA
  • 10.2.4 Key Challenges: Development and Uptake of Abatacept
  • 10.2.5 Views on Cimzia
  • 10.2.6 Treatments in the R&D Pipeline
  • 10.2.7 Views on the Prevalence of RA
• 10.3 Interview with a Professor Working in Rheumatology
  • 10.3.1 Views on the Prevalence of RA
  • 10.3.2 Views on Anti-TNF Therapies for RA
  • 10.3.3 Opinion on Biosimilars
  • 10.3.4 Key Challenges in the Market
  • 10.3.5 Key Treatment Goals

11. Conclusions

• 11.1 World Market Overview to 2023
• 11.2 The Drug Classes
• 11.3 The Leading Drugs
• 11.4 The Leading National Markets
• 11.5 The Future of the RA Drug Market

List of Tables

• Table 3.1 Biologic Agents and Mechanisms of Action
• Table 4.1 The RA Market by Submarket, 2011
• Table 4.2 The Market for RA Indications: Revenue Forecast, 2012-2023
• Table 4.3 Rheumatoid Arthritis Market: Segment Revenue Forecasts, 2012-2023
• Table 4.4 Non-Biologics for RA: Revenue Forecasts by Segment, 2012-2023
• Table 4.5 NSAIDs: Market Forecast, 2012-2023
• Table 4.6 Conventional DMARDs: Revenue Forecast, 2012-2023
• Table 4.7 The Others Submarket: Revenue Forecast, 2012-2023
• Table 4.8 The Biologics Submarket: Revenue Forecast, 2012-2023
• Table 5.1 The Leading Drugs in the RA Market: Revenues and Market Shares, 2011
• Table 5.2 The Main Drugs in the RA Market: Revenue Forecasts, 2012-2023
• Table 5.3 Celebrex: Key Facts
• Table 5.4 Celebrex: Revenue Forecast, 2012-2023
• Table 5.5 Arcoxia: Key Facts
• Table 5.6 Arcoxia: Revenue Forecast, 2012-2023
• Table 5.7 Remicade: Key Facts
• Table 5.8 Remicade: Revenue Forecast, 2012-2023
• Table 5.9 Humira: Key Facts
• Table 5.10 Humira: Revenue Forecast, 2012-2023
• Table 5.11 Enbrel: Key Facts
• Table 5.12 Enbrel: Revenue Forecast, 2012-2023
• Table 5.13 Rituxan: Key Facts
• Table 5.14 Rituxan: Revenue Forecast, 2012-2023
• Table 5.15 Orencia: Key Facts
• Table 5.16 Orencia: Revenue Forecast, 2012-2023
• Table 5.17 Simponi: Key Facts
• Table 5.18 Simponi: Revenue Forecast, 2012-2023
• Table 5.19 Actemra: Key Facts
• Table 5.20 Actemra: Revenue Forecast, 2012-2023
• Table 5.21 Cimzia: Key Facts
• Table 5.22 Cimzia: Revenue Forecast, 2012-2023
• Table 5.23 Xeljanz: Key Facts
• Table 5.24 Xeljanz: Revenue Forecast, 2012-2023
• Table 6.1 RA: The Leading National Markets, 2011
• Table 6.2 RA Drugs: Market Shares by Country, 2011 and 2023
• Table 6.3 RA Drugs: Revenue Forecasts by Country, 2012-2023
• Table 6.4 The US RA Drug Market: Revenue Forecast, 2012-2023
• Table 6.5 The EU5 RA Drug Markets: Revenue Forecasts, 2012-2023
• Table 6.6 The Japanese RA Drug Market: Revenue Forecast, 2012-2023
• Table 6.7 The Chinese RA Drug Market: Revenue Forecast, 2012-2023
• Table 6.8 The Brazilian RA Drug Market: Revenue Forecast, 2012-2023
• Table 6.9 The Indian RA Drug Market: Revenue Forecast, 2012-2023
• Table 6.10 The Russian RA Drug Market: Revenue Forecast, 2012-2023
• Table 7.1 The Corticosteroid R&D Pipeline, 2013
• Table 7.2 The Biologic R&D Pipeline, 2013
• Table 7.3 Biosimilars R&D Pipeline, 2013
• Table 7.4 Other Drugs for RA: R&D Pipeline, 2013
• Table 8.1 Leading Companies in the RA Drug Market: Revenues and Market Shares, 2011
• Table 8.2 Abbott Laboratories: Breakdown of Revenue from RA Drugs, 2011
• Table 8.3 Roche: Breakdown of Revenue from RA Drugs, 2011
• Table 8.4 Pfizer: Breakdown of Revenue from RA Drugs, 2011
• Table 8.5 Johnson & Johnson: Breakdown of Revenue from RA Drugs, 2011
• Table 8.6 Amgen: Breakdown of Revenue from RA Drugs, 2011
• Table 10.1 Strengths and Weaknesses of the RA Drug Market, 2013
• Table 10.2 Opportunities and Threats Facing the RA Drug Market, 2013-2023
• Table 10.3 Social, Technological, Economic and Political Factors Influencing the RA Drug Market (STEP Analysis), 2013-2023

List of Figures

• Figure 4.1 The RA Market: Market Shares by Submarket, 2011
• Figure 4.2 The Market for RA Indications: Revenue Forecasts, 2012-2023
• Figure 4.3 Rheumatoid Arthritis Market: Segment Revenue Forecasts, 2012-2023
• Figure 4.4 The RA Market: Market Shares by Submarket, 2017
• Figure 4.5 The RA Market: Market Shares by Submarket, 2023
• Figure 4.6 Non-Biologic Drugs: Market Shares, 2011
• Figure 4.7 Non-Biologics for RA: Market Forecasts, 2012-2023
• Figure 4.8 Non-Biologics for RA: Market Shares, 2023
• Figure 4.9 The Non-Biologic RA Drug Market: Drivers and Restraints, 2013
• Figure 4.10 NSAIDs: Revenue Forecast, 2012-2023
• Figure 4.11 Conventional DMARDs: Revenue Forecast, 2012-2023
• Figure 4.12 The Others Submarket: Revenue Forecast, 2012-2023
• Figure 4.13 The Biologics Submarket: Revenue Forecast, 2012-2023
• Figure 4.14 The Biologic RA Drug Market: Drivers and Restraints, 2013
• Figure 5.1 Key Drugs for RA: Market Shares, 2011
• Figure 5.2 Celebrex: Revenue Forecast, 2012-2023
• Figure 5.3 Arcoxia: Revenue Forecast, 2012-2023
• Figure 5.4 Remicade: Revenue Forecast, 2012-2023
• Figure 5.5 Humira: Revenue Forecast, 2012-2023
• Figure 5.6 Enbrel: Revenue Forecast, 2012-2023
• Figure 5.7 Rituxan: Revenue Forecast, 2012-2023
• Figure 5.8 Orencia: Revenue Forecast, 2012-2023
• Figure 5.9 Simponi: Revenue Forecast, 2012-2023
• Figure 5.10 Actemra: Revenue Forecast, 2012-2023
• Figure 5.11 Cimzia: Revenue Forecast, 2012-2023
• Figure 5.12 Xeljanz: Revenue Forecast, 2012-2023
• Figure 5.13 Leading RA Drugs: Market Shares, 2023
• Figure 6.1 RA: Market Shares by Country, 2011
• Figure 6.2 RA Drugs: Market Shares by Country, 2023
• Figure 6.3 The US RA Drug Market: Revenue Forecast, 2012-2023
• Figure 6.4 The EU5 RA Drug Markets: Revenue Forecasts, 2012-2023
• Figure 6.5 The Japanese RA Drug Market: Revenue Forecast, 2012-2023
• Figure 6.6 The Chinese RA Drug Market: Revenue Forecast, 2012-2023
• Figure 6.7 The Brazilian RA Drug Market: Revenue Forecast, 2012-2023
• Figure 6.8 The Indian RA Drug Market: Revenue Forecast, 2012-2023
• Figure 6.9 The Russian RA Drug Market: Revenue Forecast, 2012-2023
• Figure 7.1 The R&D Pipeline for Rheumatoid Arthritis, 2013
• Figure 8.1 Leading Companies in the RA Drug Market: Market Shares, 2011
• Figure 8.2 Abbott Laboratories: Breakdown of Revenue from RA Drugs, 2011
• Figure 8.3 Roche: Breakdown of Revenue from RA Drugs, 2011
• Figure 8.4 Pfizer: Breakdown of Revenue from RA Drugs, 2011
• Figure 8.5 Johnson & Johnson: Breakdown of Revenue from RA Drugs, 2011
• Figure 8.6 Amgen: Breakdown of Revenue from RA Drugs, 2011
• Figure 11.1 RA Drug Market Forecast: Comparison of Total Market and Market for RA Indications, 2012-2023
• Figure 11.2 RA Drug Market Forecast: Comparison of the Biologic and Non-Biologic Submarkets, 2012-2023
• Figure 11.3 The Leading RA Drugs: Revenue Projections, 2011, 2017 and 2023
• Figure 11.4 The Leading National Markets: Revenue Projections, 2011, 2017 and 2023

Companies Listed

• AB Science
• Abbott Laboratories (AbbVie)
• Ablynx
• Alliancells Bioscience
• Amgen
• AstraZeneca
• Baylor Research Institute
• Biogen Idec
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celltech
• Celltrion
• Centers for Disease Control and Prevention
• Centocor Ortho Biotech
• Dr. Reddy's Laboratories
• Eli Lilly
• EMS
• Epirus Biopharmaceuticals
• European Medicines Agency (EMA)
• Food and Drug Administration (US FDA)
• Genentech
• GlaxoSmithKline (GSK)
• Hanwha Chemical
• Hospital for Joint Diseases and Medicine
• ISIS Pharmaceuticals
• Janssen Biologics
• Janssen Biotech
• Janssen Scientific Affairs
• Johnson & Johnson
• Jyväskylä Central Hospital
• Korean Food and Drug Administration (KFDA)
• MedImmune
• Merck & Co.
• National Institute for Health and Clinical Excellence (NICE)
• New York University
• Novartis
• Pfizer
• Philogen
• Regeneron Pharmaceuticals
• Roche
• Sanofi
• The Hospital for Special Surgery
• The World Health Organization (WHO)
• TSH Biopharm
• UCB Pharma
• Vertex Pharmaceuticals